{"disease":{"id":"non-small-cell-lung-cancer-metastatic","name":"non small cell lung cancer metastatic"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06557967","title":"Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":22517,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT05537922","title":"I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":2200,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT05908799","title":"Emulation of the KEYNOTE-189 Trial Using Electronic Health Records","phase":"","overall_status":"COMPLETED","enrollment_count":1854,"lead_sponsor_name":"Aetion, Inc.","has_results":false},{"nct_id":"NCT07222566","title":"Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1410,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05339568","title":"Patient's Whole Process Follow-up Management(HOPE-1)","phase":"","overall_status":"RECRUITING","enrollment_count":1268,"lead_sponsor_name":"Qianfoshan Hospital","has_results":false},{"nct_id":"NCT04613596","title":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":806,"lead_sponsor_name":"Mirati Therapeutics Inc.","has_results":false},{"nct_id":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT07144280","title":"A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":680,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03533127","title":"A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":648,"lead_sponsor_name":"Luye Pharma Group Ltd.","has_results":false},{"nct_id":"NCT01966003","title":"Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":642,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT04205812","title":"Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":583,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT03319628","title":"First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":523,"lead_sponsor_name":"Mersana Therapeutics","has_results":false},{"nct_id":"NCT07524257","title":"ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":494,"lead_sponsor_name":"ImmunityBio, Inc.","has_results":false},{"nct_id":"NCT04623775","title":"A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":468,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT03732482","title":"Temozolomide Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Non Small Cell Lung Cancer Brain Metastases","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Taizhou Hospital","has_results":false},{"nct_id":"NCT06416410","title":"JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":392,"lead_sponsor_name":"Allist Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04154956","title":"SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":389,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT07111104","title":"Survival Efficacy of Combined Radiotherapy and Immunotherapy in Patients With Metastatic Non-small Cell Lung Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":350,"lead_sponsor_name":"Hopitaux Prives de Metz, Groupe UNEOS","has_results":false},{"nct_id":"NCT05107674","title":"A Study of NX-1607 in Adults With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":345,"lead_sponsor_name":"Nurix Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03774732","title":"PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":327,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT03207867","title":"A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":315,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02740985","title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":313,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03477474","title":"Registry of Guardant360® Use and Outcomes In People With Advanced Cancer","phase":"","overall_status":"TERMINATED","enrollment_count":311,"lead_sponsor_name":"Guardant Health, Inc.","has_results":false},{"nct_id":"NCT03956641","title":"Evolution of the Physical Condition in Treated Cancer Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Centre Paul Strauss","has_results":false},{"nct_id":"NCT07190677","title":"First-line Therapy With Nivolumab Plus Ipilimumab in Combination With Chemotherapy for Metatastatic NSCLC (NICReWo Trial)","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT03727477","title":"Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib","phase":"","overall_status":"COMPLETED","enrollment_count":291,"lead_sponsor_name":"Intergroupe Francophone de Cancerologie Thoracique","has_results":false},{"nct_id":"NCT04697446","title":"External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC","phase":"","overall_status":"UNKNOWN","enrollment_count":279,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT04619004","title":"HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":277,"lead_sponsor_name":"Daiichi Sankyo","has_results":true},{"nct_id":"NCT04925284","title":"Study of XB002 in Subjects With Solid Tumors (JEWEL-101)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":269,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT04009122","title":"Evaluation of the Quality of Life of Patients With Metastatic Non-small Cell Lung Cancer With Supplementary Therapy With IGEN-0206","phase":"NA","overall_status":"COMPLETED","enrollment_count":266,"lead_sponsor_name":"Igen BioLab SLU","has_results":false},{"nct_id":"NCT03469960","title":"Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":265,"lead_sponsor_name":"Intergroupe Francophone de Cancerologie Thoracique","has_results":false},{"nct_id":"NCT05853887","title":"Liquid Biopsy Based NGS in Newly Diagnosed NSCLC","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":260,"lead_sponsor_name":"Charu Aggarwal","has_results":false},{"nct_id":"NCT03829501","title":"A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":222,"lead_sponsor_name":"Kymab Limited","has_results":true},{"nct_id":"NCT06060613","title":"Safety and Efficacy of OBX-115 in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":208,"lead_sponsor_name":"Obsidian Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04923945","title":"Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":203,"lead_sponsor_name":"Hutchison Medipharma Limited","has_results":false},{"nct_id":"NCT03424980","title":"A Study to Evaluate Effectiveness and Safety of Tyrosine Kinase Inhibitors","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Tang-Du Hospital","has_results":false},{"nct_id":"NCT07462728","title":"Phase III, Multicenter, Randomized Controlled Clinical Study of Three-Dimensional Radiotherapy for Primary Tumors in Non-Oligometastatic Stage IV Non-Small Cell Lung Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Guizhou Medical University","has_results":false},{"nct_id":"NCT03345810","title":"Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"AIO-Studien-gGmbH","has_results":false},{"nct_id":"NCT05835570","title":"Integrin αvβ6-targeted PET in Malignant Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Zhongnan Hospital","has_results":false},{"nct_id":"NCT03235765","title":"Cancer Panel From Blood of Lung Cancer Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT06784193","title":"Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Olema Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT03761017","title":"MGD019 DART® Protein in Unresectable/Metastatic Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":162,"lead_sponsor_name":"MacroGenics","has_results":false},{"nct_id":"NCT05364073","title":"Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":160,"lead_sponsor_name":"ArriVent BioPharma, Inc.","has_results":false},{"nct_id":"NCT02376699","title":"Safety Study of SEA-CD40 in Cancer Patients","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":159,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT04836728","title":"Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":156,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT03133546","title":"Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":155,"lead_sponsor_name":"ETOP IBCSG Partners Foundation","has_results":true},{"nct_id":"NCT03911219","title":"Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy","phase":"","overall_status":"COMPLETED","enrollment_count":154,"lead_sponsor_name":"iOMEDICO AG","has_results":false},{"nct_id":"NCT02922764","title":"A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":146,"lead_sponsor_name":"Inspirna, Inc.","has_results":false},{"nct_id":"NCT03363685","title":"Verification of Novel Survival Prediction Algorithm for Patients With NSCLC Spinal Metastasis","phase":"","overall_status":"UNKNOWN","enrollment_count":140,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT03123783","title":"CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"Apexigen America, Inc.","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}